Lorigerlimab for Pancreatic Cancer with Specific Gene Changes
This study is testing a drug called lorigerlimab for people with pancreatic adenocarcinoma (a type of pancreatic cancer) that has spread. You might be able to join if your cancer has specific changes in genes like BRCA1, BRCA2, or PALB2. The main goal is to see how many people respond to lorigerlimab, meaning their tumor shrinks or stops growing. The study plans to enroll about 40 participants. The current status of the study is unclear, so it's not known if they are actively enrolling new patients.
- Study design
- This is an interventional study planning to enroll 40 participants. It is testing the drug lorigerlimab given intravenously every three weeks.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your response to treatment will be measured from the start of the study up to 60 months.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Lorigerlimab (MGD019) in Patients With Pancreatic Adenocarcinoma and Homologous Recombination Deficiency
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Peter J Hosein, MBBS · PRINCIPAL_INVESTIGATOR · University of Miami
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Objective Response Rate (ORR)Baseline, Up to 60 months
Objective Response Rate (ORR) is defined as the proportion or percentage of patients with confirmed partial (PR) or complete (CR) best overall response.